Company Overview of Abmaxis, Inc.
Abmaxis, Inc., a biopharmaceutical company, engages in the discovery, optimization, and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. It offers Abmaxis in-silico Immunization (AISIM), an antibody engineering technology platform, which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The company was incorporated in 2000 and is based in Santa Clara, California. As of May 9, 2006, Abmaxis, Inc. operates as a subsidiary of Merck & Co., Inc.
3303 Octavius Drive
Santa Clara, CA 95054
Founded in 2000
Key Executives for Abmaxis, Inc.
Similar Private Companies By Industry
|TheraTarget, Inc.||United States|
|Hepregen Corporation||United States|
|Tranzderm Solutions||United States|
|Axygen Biosciences, Inc.||United States|
|PathoGene, L.L.C.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Abmaxis, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.